Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232625 | 0.92 | AKT1 (0.40) | ADORA1SLC2A1ADORA3TGM2MAPK8 | |
| SCHEMBL3227453 | 0.84 | AURKA (0.38) | ADORA1SLC2A1AKR1C1ADORA3TGM2 | |
| SCHEMBL3234022 | 0.83 | SYK (0.42) | ADORA1AKR1C1ADORA3MAPK8MAPK10 | |
| SCHEMBL3233767 | 0.83 | PTGS2 (0.34) | ADORA1SLC2A1ADORA3TGM2MAPK8 | |
| SCHEMBL3227553 | 0.82 | MAPT (0.41) | ADORA1AKR1C1ADORA3ADORA2ATACR3 | |
| SCHEMBL3224000 | 0.82 | SYK (0.44) | ADORA1AKR1C1ADORA3MAPK8MAPK10 | |
| SCHEMBL3261619 | 0.82 | VCP (0.42) | ADORA1AKR1C1ADORA3MAPK8ADORA2A | |
| Dimethylamine SCHEMBL3266676 | 0.82 | SYK (0.40) | ADORA1AKR1C1ADORA3MAPK8MAPK10 | |
| SCHEMBL3224082 | 0.81 | AKR1C1 (0.43) | ADORA1AKR1C1ADORA3MAPK8MAPK10 | |
| SCHEMBL3264006 | 0.81 | SYK (0.42) | ADORA1AKR1C1ADORA3MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | claimed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | ADORA1 2916/4885SLC2A1 4009/4885AKR1C1 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.